More articles about Reproductive Health

Noninvasive prenatal screening for trisomies and sub-chromosomal alterations uncovered a fragile site expansion and related deletion present in mothers but not fetuses.

Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.

The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.

Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.

The company is now seeking commercial partners in Brazil to make the Iona test available in the country.

The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.

A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.

The Salt Lake City-based firm expects to launch a test in the infertility space this year and is also involved in endometriosis therapeutics development.

Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.

The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.

The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.

The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The companies will develop a platform for sample and workflow management, genetic data interpretation, and external client communication.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

Eone-Diagnomics will offer its Gen Screen non-invasive prenatal test in certain Asian markets in partnership with cord blood service provider Cordlife.

The test is offered to couples who have had an affected pregnancy, with the goal of providing a diagnosis to enable early prenatal or preimplantation genetic testing. 

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.

The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.